Natrol Inc

Natrol — CL King's Best Ideas Conference 2007

18 slides from Natrol's conference presentation, Sep 19, 2007

  1. Slide 1: Maximizing shareholder returns and exceeding customer expectations

    Maximizing shareholder returns and exceeding customer expectations NATROL CL King’s Best Ideas Conference September 2007 Craig Cameron Chief Operating Officer

  2. Slide 2: Safe harbor

    2 This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Natrol’s expectations or forecasts of future events, can be affected b

  3. Slide 3: Company profile

    3 Company profile Established 1980 Nasdaq symbol - NTOL Current market cap $47.7 FY December 31, 2006 Annual sales $65.6 Gross profit 28.4 Operating income 0.7 Comparative First half 2006 vs. First half 2007 2006 2007 Sales $33.5 $38.3 Gross profit 14.1 18.1 Operating income 0.3 1.5 Balance sheet as

  4. Slide 4: Key investment highlights

    4 Targets a growing, but fragmented, $22B market Significant acquisition opportunities Well developed operating infrastructure Broad distribution channels Strong brands across multiple product categories New management working through a financial and operational turn-around Multiple, varied opportun

  5. Slide 5: A portfolio of strong brands

    5 A portfolio of strong brands

  6. Slide 6: 54,000 points of distribution in USA

    6 54,000 points of distribution in USA HEALTH FOOD CLUB/MM GYMS CATALOGS AARP ® Swanson Health Products® DRUG STORE E-Commerce GROCERY International distribution to over 40 countries

  7. Slide 7: Manufacturing capabilities and quality

    7 Manufacturing capabilities 200,000,000 pills per month capacity 3,000,000 bottles per month capacity Meets all FDA requirements 33% utilization Manufacturing capabilities and quality Quality assurance & quality control State-of-the art laboratory facilities Strong focus on R&D and QA/QC Microbiolo

  8. Slide 8: MRI acquisition

    8 MRI acquisition On June 1, 2007 completed the acquisition of MRI, maker of the NO2 line of products Up front cash $8.4 million Former owner has potential to receive an earnout capped at $80.0 million with payments amounting to not more than 4x EBIT MRI brand has the premier position in the sports

  9. Slide 9: NATR@L

    NATR@L

  10. Slide 10: Past months accomplishments

    10 Past 18 months accomplishments Strengthened management and board New executives recruited for roles of CEO, COO, VP Marketing and Director, UK Restructured board of directors with growth company experience Stabilized and consolidated core business Gross margin improvement from 34% to 47% Redirect

  11. Slide 11: Last months accomplishments cont'd

    11 Last 18 months accomplishments cont’d Finalized three accretive acquisitions Established M&A capability Nu Hair® and Shen Min® brands U.S. rights to Promensil® brand MRI business Integration capable organization Balanced asset portfolio Divestment of real estate Sale price $26M; realized $12M cas

  12. Slide 12: Business performance – gross margin

    12 Business performance – gross margin Unique IP Best practice marketing M&A International Strong board/management 54,000 pts distribution Logistics and mfg Strong balance sheet 54,000 pts distribution Logistics and mfg Strong balance sheet M&A International New board/management 54,000 pts distribut

  13. Slide 13: Stock price performance

    13 Stock price performance $1.00 $1.50 $2.00 $2.50 $3.00 $3.50 $4.00 $4.50 $5.00 8/1/06 10/1/06 12/1/06 2/1/07 4/1/07 6/1/07 8/1/07

  14. Slide 14: New growth opportunity?

    14 New growth opportunity? Approximately 110 million people or 38.0% of the U.S. population is over the age of 45 (2005 Census) This age group has more disposable income than any other market segment This segment spends money to look and feel healthier and younger, e.g. the growth of health spas and

  15. Slide 15: Case study – joint relief

    15 Case study– joint relief 34.0% of households have at least one member suffering from joint and neck pain in the last six months (AC Nielson) 15.8 million people in the US are affected by osteoarthritis while the preventative market is estimated to be 50 million people Joint relief supplements rep

  16. Slide 16: Natrol's anti-aging opportunity

    16 Natrol’s anti-aging opportunity Natrol is developing a revolutionary new anti-aging product line targeting the over 45 age demographic With millions of older Americans trying to look and feel healthier and younger the market opportunity may be as large, or larger than, joint relief If 1% of the o

  17. Slide 17: Anti-aging product status

    17 Status Objective Create a unique line of premium, patented, proven anti-aging supplements Products Core platform of four products Based on leading edge science Support from top researchers Status Finalizing first product and patent New clinical trials being planned Early stage work on positioning

  18. Slide 18: Natrol/MRI – positioned for growth

    18 Natrol/MRI – positioned for growth Solid core business 54,000 existing points of distribution in the U.S. Strong balance sheet – no debt Experienced acquisition and integration team Expanding international presence Seasoned board and management New anti-aging products and marketing under developm

Natrol — CL King's Best Ideas Conference 2007 on 6ix